Theravac

Theravac is an investigational **therapeutic melanoma vaccine** comprising a genetically detoxified recombinant *Bordetella pertussis* adenylate cyclase toxin vector coupled through its catalytic site to the HLA-A2-restricted tyrosinase A2 epitope YMDGTMSQV. The vector targets CD11b-positive antigen-presenting cells through alphaMbeta2 integrin, enabling processing and MHC class I presentation of the tyrosinase epitope to induce melanoma-directed cytotoxic T-cell responses. It was evaluated in a Phase I/II study in patients with advanced metastatic melanoma. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/698993))

Brand names

THERAVAC

Other names

recombinant Bordetella pertussis adenylate cyclase toxin-tyrosinase A2 epitope vaccine